Laboratoires Serono S.a.

Merck Serono S. A.

Siena Biotech S.p.a.

Russel J Thomas

Jean-Pierre Gotteland

Matthias Schwarz

Agnes Bombrun

Dominique Swinnen

Thomas Rueckle

Pascale Gaillard

Marco Antonio Biamonte

Isabelle Jeanclaude-Etter

Jean-Francois Pons

Agnès Bombrun

Galla Pericot Mohr

Giacomo Minetto

Marta Bellini

Jean-François Pons

Matteo Betti

Wiedenau Paul H H

The present invention relates to sulfonamide derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are useful in the treatment of neuronal disorders, autoimmune diseases, cancer and cardiovascular diseases. Furthermore, said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and -3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. Formula (I) IAris a substituted or unsubstituted aryl or heteroaryl group; X is O or S, preferably O; Ara substituted or unsubstituted arylene or heteroarylene group; Rand Rare independently selected from the group consisting of hydrogen and a C-C-alkyl group. 

Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors

An azole derivative of formula (I) a medicament that contains the azole derivative of formula (I), a method of treating a disease with the azole derivative of formula (I), and a method of preparing the azole derivative of formula (I).

Azole methylidene cyanide derivatives and their use as protein kinase modulators

The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an aminocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; Rand Rare independently from each other is selected from the group consisting of hydrogen or C-C-alkyl; Rand Rare each independently from each other selected from the group consisting of H, hydroxy, C-Calkyl, carboxy, C-Calkoxy, C-Calkyl carboxy, C-Calkenyl carboxy, C-Calkynyl carboxy, amino or Rand Rmay form an unsaturated or saturated heterocyclic ring, whereby at least one of Ror Ris not a hydrogen or C-Calkyl 

Aryl dicarboxamides

Growing community of inventors

Siena, Italy

Russel J Thomas